AI Article Synopsis

  • The study aimed to investigate the prevalence and risk factors associated with gestational diabetes mellitus (GDM) at University College Hospital in Ibadan, Nigeria.
  • Over a two-year period, records of 765 women referred for oral glucose tolerance testing were analyzed, revealing a crude prevalence rate of 13.9%, with most diagnoses occurring in the third trimester.
  • Key risk factors for GDM included a positive family history of diabetes, age over 30, and significant fasting glucose levels; importantly, there was no identified BMI threshold as a risk factor for women in their first trimester.

Article Abstract

Aims: This study aimed to determine the prevalence and relationships with known risk factors of gestational diabetes mellitus (GDM) at University College Hospital, Ibadan, Nigeria.

Methods: Records of all women referred for oral glucose tolerance testing at the metabolic research unit of the Hospital over a 2 year period were reviewed. Diagnosis of GDM was made in accordance with WHO criteria. GDM diagnosis was classified as early and late based on a gestational age <24 weeks and >24 weeks respectively. Body mass index (BMI) measurements were performed for women who presented in the first trimester. Various statistical tools including student t test and Pearson's coefficient of correlation were used.

Results: A total of 765 records were reviewed. The crude prevalence rate was 13.9%. The prevalence rate among women in the first trimester was highest at 17.4% although most of the diagnoses were made in the third trimester (55.7%). A positive family history and a family history of GDM were associated significantly with a higher fasting and 2 h post-load glucose values, irrespective of current GDM diagnosis. The most consistent associations with a diagnosis of GDM were a positive family history and a history of GDM. Age above 30 years at oral glucose testing also showed significant association. There was no BMI threshold associated with a significant risk of GDM for those women presenting in the first trimester.

Conclusions: GDM is a common metabolic condition in Nigeria. Onset before the 24th week of pregnancy is not uncommon.

Download full-text PDF

Source
http://dx.doi.org/10.1136/jcp.2010.087098DOI Listing

Publication Analysis

Top Keywords

oral glucose
12
family history
12
gdm
9
glucose tolerance
8
tolerance testing
8
gestational diabetes
8
diabetes mellitus
8
diagnosis gdm
8
gdm diagnosis
8
prevalence rate
8

Similar Publications

Background: As a novel oral anti-hyperglycemic agent, sodium-glucose cotransporter 2 inhibitors (SGLT2-i) have been demonstrated to improve cardiovascular outcomes in acute myocardial infarction (AMI) patients with type 2 diabetes mellitus (T2DM). However, the mechanism responsible for the beneficial effects remains unclear. Recently, extensive studies have demonstrated a close relationship between elevated fasting triglyceride-glucose (TyG) index and the risk of AMI.

View Article and Find Full Text PDF

Purpose: Two-shot γ-aminobutyric acid (GABA) difference editing techniques have been used widely to detect the GABA H4 resonance at 3.01 ppm. Here, we introduce a single-shot method for detecting the full GABA H2 resonance signal, which avoids contamination from the coedited M macromolecules.

View Article and Find Full Text PDF

Background: In uterine cervical cancer (UCC), tumour staging is performed according to the 2018 International Federation of Gynecology and Obstetrics (FIGO) system, where imaging is incorporated, or the more generic Tumour Node Metastasis (TNM) classification. With the technical development in diagnostic imaging, continuous prospective evaluation of the different imaging methods contributing to stage determination is warranted. The aims of this interim study were to (1) evaluate the performance of radiological FIGO (rFIGO) and T staging (rT) with 2-fluorine-18-fluoro-deoxy-glucose (2[18F]-FDG)-positron emission tomography with computed tomography (PET/CT) and with magnetic resonance imaging (PET/MRI), compared to clinical FIGO (cFIGO) and T (cT) staging based on clinical examination and conventional imaging, in treatment-naïve UCC, and to (2) identify possible MRI biomarkers for early treatment response after radiotherapy.

View Article and Find Full Text PDF

Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study.

Sci Rep

January 2025

Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, P.O. Box: 13145-784, Tehran, Iran.

The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year follow-up period in 575 adult patients with uncontrolled T2DM on a triple OHA regimen and who were unwilling to initiate insulin therapy. Overall, 92.

View Article and Find Full Text PDF

Introduction: Several cardiovascular outcome trials have been conducted to assess the cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on cardiorenal outcomes in patients with type-2 diabetes (T2D). However, the strict requirements of randomised controlled trials to avoid most confounding factors are at the expense of external validity. Using national real-world data, we aimed to evaluate the effectiveness of GLP-1RAs in association with metformin especially on cardiovascular events, hospitalisation for heart failure and all-cause death in comparison with other diabetes treatment schemes using dipeptidyl peptidase IV inhibitors, sulfonylureas/glinides or insulin also associated with metformin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!